Product Description

NHERTU is a prescription medicine used to treat adults who have:

• Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
  • For metastatic disease, or
  • Have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
• HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
  • For metastatic disease, or
  • Your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
• Non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
  

  ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

• Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.

How to use

• You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
• ENHERTU is given 1 time every three weeks (21-day treatment cycle).
• Your healthcare provider will decide how many treatments you need.
• Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
• Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
• If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Uses

Treatment of Breast cancer
Treatment of Cancer

Side Effects

The most common side effects of ENHERTU, when used in people with metastatic breast cancer and HER2-mutant non-small cell lung cancer include:

Storage

Store in a refrigerator (2 - 8)℃